Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF PROFIT AND LOSS AND OTHER COMPREHENSIVE LOSS

v3.23.1
CONSOLIDATED STATEMENTS OF PROFIT AND LOSS AND OTHER COMPREHENSIVE LOSS - USD ($)
 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disclosure of disaggregation of revenue from contracts with customers [line items]    
Revenue $ 8,561
Cost of revenue 9,926  
Gross profit (loss) (1,365)  
Operating expenses:    
Sales and Marketing 26,616 13,818
Research & Development 397,109 433,743
General and Administrative 5,307,671 1,286,118
Total operating expenses 5,731,396 1,733,679
Operating loss (5,732,761) (1,733,679)
Other income (expense):    
Interest expense (15,468) (15,438)
Other income (expense) 290,466 (753)
Total other income (expense) 274,998 (16,191)
Loss before income taxes (5,457,763) (1,749,870)
Net loss (5,457,763) (1,749,870)
Net loss attributable to non-controlling interest (269) (41,043)
Net loss attributable to Virax (5,457,494) (1,708,827)
Other comprehensive (loss)    
Foreign currency adjustment (111) (965)
Comprehensive loss (5,457,652) (1,748,905)
Comprehensive income, attributable to non-controlling interests (269) (78,065)
Comprehensive loss attributable to Virax $ (5,457,383) $ (1,670,840)
Basic and diluted weighted average shares outstanding    
Ordinary shares 10,629,835 9,563,260
Diluted ordinary shares 10,629,835 9,563,260
Basic and diluted net loss per share    
Basic net loss per share $ (0.51) $ (0.18)
Diluted net loss per share $ (0.51) $ (0.18)